Lymphangioleiomyomatosis


Article Author:
Karam Khaddour


Article Editor:
Maryna Shayuk


Editors In Chief:
Mohamed Alhajjaj
Fatima Anjum
Pramil Cheriyath


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Frank Smeeks
Kristina Soman-Faulkner
Radia Jamil
Patrick Le
Sobhan Daneshfar
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
3/2/2019 5:46:23 PM

Introduction

Lymphangioleiomyomatosis (LAM) is a primary disease of the lung parenchyma that is caused by abnormal growth of smooth muscle cells in the lung vasculature, lymphatics, and alveoli that leads to the formation of multiple cysts in the lungs bilaterally and respiratory symptoms, mainly dyspnea on exertion. The main involved organs are the lungs, but it can have extrapulmonary manifestations including in the kidneys causing angiomyolipomas which are benign tumors or can sometimes cause perivascular epithelioid cell tumors with visceral organ involvement.

Etiology

LAM can present sporadically or can be associated with tuberous sclerosis. The sporadic form affects almost only premenopausal women although some cases were reported to occur in men.[1]

Epidemiology

The sporadic form prevalence is unknown; however, one study that was done in 7 countries estimated the prevalence of 3 to 7 cases per million in women.[2] The form it associate which with tuberous sclerosis is prevalent in 30% to 80% of female patients.[3]

Pathophysiology

Estrogen is thought to play an important role in the development of the sporadic form of LAM through stimulation of cell growth that is mediated by estrogen receptors alpha (ERa). Although the mechanism is not entirely understood, researchers hypothesize that estrogen can cause modulation of growth signaling pathways that could lead to uncontrolled cell growth.[4] The observation that patient with LAM have progression of the disease during pregnancy and oral estrogen use supports this. Estrogen use is also known to cause worsening of the disease and in vitro studies have shown that LAM cells express increased ERa.[5] Mutations in tuberous sclerosis complex-2 gene (TSC2) have been proven to have mutations in patients with sporadic LAM.[6] The previously mentioned gene along with TSC1 encodes proteins responsible for inhibition of the mammalian target of rapamycin (mTOR) which is an intracellular signaling pathway the regulated cell proliferation.[7] It affects these 2 genes in the hereditary form of LAM which occurs with tuberous sclerosis.

History and Physical

LAM is insidious but can present with acute respiratory manifestations during pregnancy or after use of oral estrogen in females in reproductive age. Dyspnea is the most common presenting symptom which can occur during rest and increases with exertion. It could be mistaken and treated as chronic obstructive pulmonary disease (COPD) or asthma. Other manifestations that are less common include a productive cough and hemoptysis. Wheezing could be heard on physical examination in some patients. Also, pleural effusions and pneumothorax can occur in a small percentage of patients with LAM.[8]

Evaluation

Laboratory Studies

Patients with LAM do not have abnormal complete blood count (CBC) or comprehensive metabolic panel (CMP) unless they have other medical conditions. There are no definitive tests or biomarkers that can establish the diagnosis of LAM. However, some studies suggest that it could measure vascular endothelial growth factor D (VEGF-D in patients with suspicion of LAM as numbers equal to 800 pg/mL has high sensitivity and specificity.[9] Pleural effusion is present is usually chylomicron due to lymphatic obstruction with the abnormal growth. Triglyceride levels are usually greater than 110 mg/dL.

Pulmonary Function Testing

Most of the patients with LAM have an obstructive pulmonary pattern and expected to have decreased FEV1/FVC and decreased DLCO on spirometry.  Some reversibility could be noticed on the administration of bronchodilators during testing, and that is why some patients with respiratory symptoms could be diagnosed initially as having asthma. It also uses six-minute walk test in clinical practice in patients with LAM to assess for hypoxia and requirements of oxygen.

Imaging

Chest x-ray shows none specific findings in patients with LAM. The cystic disease difficult to recognize on a plain chest x-ray, and it could see only non-specific findings of pneumothorax or pleural effusions if present. High-resolution computed tomography (HRCT) has a high sensitivity and specificity of detecting the disease and has been suggested as a modality for screening patients who suspected of having LAM.[10] On HRCT, many small thin-walled cysts can be seen bilaterally in a diffuse distribution in the lungs. Septal thickening can be seen, and usually, there is no associated lymphadenopathy.

Biopsy

Biopsy remains the gold standard for the diagnosis of LAM where the characteristic abnormal smooth muscle-like cells can be seen under microscopy. The best approach for biopsy is surgically through either video-assisted thoracoscopy, trans-bronchial lung biopsy or surgical wedge resection. There are no guidelines of the best approach for the biopsy. Trans-bronchial lung biopsy has a lower yield and higher false negative compared to surgical biopsy. However, the decision based on the in-site experience, patient comorbidities, and wishes.

Pathology

The characteristic findings of LAM are smooth muscle cell proliferation in the walls of the alveoli and vascular bed in the lung tissue on a hematoxylin-eosin stain (H and E). Pathology could show cystic spaces. Immunohistochemical staining helps to establish the diagnosis and is positive for HMB-45, actin, and myosin. It also finds estrogen and progesterone receptors on the stain of the tissue samples. There have been cases with a diagnosis of LAM through cytology by seeing the smooth muscle-like cells and positive stains, but this remains of low yield compared to tissue biopsy.[11]

Treatment / Management

Management is aimed at controlling the symptoms, improving quality of life and slowing the progression of the disease.

Bronchodilators

Bronchodilators are used for symptomatic control and relief of symptoms in patients who show reversibility on PFTs. Usually, beta-agonists and anticholinergic used in the treatment. Studies have shown benefit and reversibility of airflow obstruction in patients with LAM treated with albuterol and ipratropium after adjusting for smoking and asthmatic status.[12]

Respiratory Rehabilitation

Studies have shown that respiratory rehabilitation in patients with decreased functional capacity and respiratory symptoms benefit from it. It encourages all health care professionals to consider patients with LAM to have respiratory rehabilitation to increase endurance and improve quality of life.[13]

Medication

Sirolimus is the only FDA-approved drug to treat LAM. Sirolimus is a (mTOR) inhibitor that controls the abnormal proliferation and growth of smooth muscle cells in the lung parenchyma and is effective and safe. The medication has shown the ability to prevent the worsening of lung function, respiratory symptoms and improve quality of life.[14] Everolimus is an alternative in patients who cannot tolerate sirolimus or have allergies but has not been approved by FDA for this purpose, and its use is still off-label.

Hormonal modulating therapy has been hypothesized to be an option for treatment given the role of estrogen. Selective estrogen receptor modulator could play a role in the treatment of the disease. However, there have been no clinical trials assessing the efficacy of these medications. One study assesses the safety of letrozole in postmenopausal women with LAM, but the study did not conclude with accurate results given the approval of the sirolimus when letrozole study was recruiting patients.

Lung Transplantation

Lung transplantation remains the best option in a patient who progresses despite supportive and medical treatment and worsening of symptoms and lung function capacities. However, many anecdotal case reports mentioned recurrence with LAM after lung transplantation raising a question to the curative role of this surgical treatment modality.

Prognosis

It has shown mortality to be longer of what has been reported in the previous decade. The median transplant-free survival in patients with LAM estimated to be 29 years from symptom onset and 23 years from diagnosis.[15] Given the possibility of recurrence after lung transplantation, many experts now consider the disease to be a low-grade neoplasm.

Complications

All patients with LAM should be advised to avoid the use of estrogen-containing oral contraceptive pills given the increased rate of worsening of the symptoms with their use. Progesterone based oral contraceptives appear to be safe and could be an alternative. Pregnancy can also increase the risk of worsening of symptoms and complications, but patients with LAM reported to have multiple pregnancies without complications. Patients with LAM should receive influenza and pneumococcal vaccination.

Enhancing Healthcare Team Outcomes

Awareness of the possible complications and drug influence in this conditon is a key concept in the diagnosis and treatment of LAM -lymphangioleiomyomatosis.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Lymphangioleiomyomatosis - Questions

Take a quiz of the questions on this article.

Take Quiz
A young female patient presents with progressive shortness of breath. She has been previously been worked up for her disease and she has repeatedly presented with pneumothorax, chylothorax, and hemoptysis. What would her lung biopsy most likely reveal?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
The chest x-ray shows cystic air space disease and a small pleural effusion in a 35-year-old female with progressive shortness of breath. She has previously had chylothorax and pneumothorax. What does the lung biopsy most likely suggest?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements about benign lung tumors is incorrect?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A young female patient presents with progressive shortness of breath. She has been worked up for her disease, and she has repeatedly presented with pneumothorax, chylothorax, and hemoptysis. She has had a lung biopsy that showed thin walled cystic air spaces and patchy, disordered, clustered to nodular proliferation of bland spindled and cuboidal epithelioid cells around airways, lymphatics, and blood vessels. These bland cells expressed HMB45 and SMA in immunohistochemistry studies. What is the diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is true regarding lymphangioleiomyomatosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is seen in patients with lymphangiomyomatosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is seen almost exclusively in women?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old female comes into the office with the chief complaint of shortness of breath. She was diagnosed with asthma four years ago and was treated with albuterol inhalers. However, she noticed that her dyspnea increased during her recent pregnancy six months ago. Vital signs are temperature of 37.5 C, blood pressure 120/68 mmHg, heart rate of 69 bpm, and oxygen saturation of 89% on ambient air. Her chest auscultation reveals diminished breath sounds over the middle lung zone without crackles or wheezing. The rest of the physical exam is unremarkable. What is the best next step in diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 30-year-old female presents for contraception. She has a past medical history significant for lymphangioleiomyomatosis, essential hypertension and hyperlipidemia. The patient has one child and is not sure if she wants to have other children. Her medications include ipratropium inhaler as needed, amlodipine and atorvastatin. What of the following is a treatment option for this patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 42-year-old female with tuberous sclerosis was recently diagnosed with lymphangioleiomyomatosis (LAM). She had transbronchial biopsy and a specimen was sent for histopathology studies. Which of the following immunohistochemical stain would strongly suggest a diagnosis of LAM?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Lymphangioleiomyomatosis - References

References

Wakida K,Watanabe Y,Kumasaka T,Seyama K,Mitani K,Hiraki T,Kamimura G,Nagata T,Nakamura Y,Sato M, Lymphangioleiomyomatosis in a Male. The Annals of thoracic surgery. 2015 Sep     [PubMed]
Harknett EC,Chang WY,Byrnes S,Johnson J,Lazor R,Cohen MM,Gray B,Geiling S,Telford H,Tattersfield AE,Hubbard RB,Johnson SR, Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM : monthly journal of the Association of Physicians. 2011 Nov     [PubMed]
Cudzilo CJ,Szczesniak RD,Brody AS,Rattan MS,Krueger DA,Bissler JJ,Franz DN,McCormack FX,Young LR, Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013 Aug     [PubMed]
Yu J,Astrinidis A,Howard S,Henske EP, Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. American journal of physiology. Lung cellular and molecular physiology. 2004 Apr     [PubMed]
Prizant H,Hammes SR, Minireview: Lymphangioleiomyomatosis (LAM): The     [PubMed]
Yu J,Astrinidis A,Henske EP, Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. American journal of respiratory and critical care medicine. 2001 Oct 15     [PubMed]
Zoncu R,Efeyan A,Sabatini DM, mTOR: from growth signal integration to cancer, diabetes and ageing. Nature reviews. Molecular cell biology. 2011 Jan     [PubMed]
Ryu JH,Moss J,Beck GJ,Lee JC,Brown KK,Chapman JT,Finlay GA,Olson EJ,Ruoss SJ,Maurer JR,Raffin TA,Peavy HH,McCarthy K,Taveira-Dasilva A,McCormack FX,Avila NA,Decastro RM,Jacobs SS,Stylianou M,Fanburg BL, The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. American journal of respiratory and critical care medicine. 2006 Jan 1     [PubMed]
Chang WY,Cane JL,Blakey JD,Kumaran M,Pointon KS,Johnson SR, Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respiratory research. 2012 Apr 18     [PubMed]
Hagaman JT,Schauer DP,McCormack FX,Kinder BW, Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. American journal of respiratory and critical care medicine. 2010 Jun 15     [PubMed]
Rivera G,Gokaslan T,Kurian EM, Lymphangioleiomyomatosis diagnosed by effusion cytology: A case report. Journal of cytology. 2015 Oct-Dec     [PubMed]
Taveira-DaSilva AM,Steagall WK,Rabel A,Hathaway O,Harari S,Cassandro R,Stylianou M,Moss J, Reversible airflow obstruction in lymphangioleiomyomatosis. Chest. 2009 Dec     [PubMed]
Araujo MS,Baldi BG,Freitas CS,Albuquerque AL,Marques da Silva CC,Kairalla RA,Carvalho CR,Carvalho CR, Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. The European respiratory journal. 2016 May     [PubMed]
McCormack FX,Inoue Y,Moss J,Singer LG,Strange C,Nakata K,Barker AF,Chapman JT,Brantly ML,Stocks JM,Brown KK,Lynch JP 3rd,Goldberg HJ,Young LR,Kinder BW,Downey GP,Sullivan EJ,Colby TV,McKay RT,Cohen MM,Korbee L,Taveira-DaSilva AM,Lee HS,Krischer JP,Trapnell BC, Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England journal of medicine. 2011 Apr 28     [PubMed]
Oprescu N,McCormack FX,Byrnes S,Kinder BW, Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013 Feb     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pulmonary. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pulmonary, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pulmonary, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pulmonary. When it is time for the Pulmonary board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pulmonary.